The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes
Open accessAbstract
Aims To evaluate the ability of vildagliptin and metformin to sustain reductions in HbA 1c over a 1‐year treatment period in drug‐naïve patients with Type 2 diabetes (Type 2 DM). Methods Double‐blind, randomized, multicentre, active‐controlled, parallel‐group study of 52‐week treatment with vildagliptin (100 mg daily, n = 526) or metformin (titrated to 2000 mg daily, n = 254) in drug‐naïve patients (baseline HbA 1c = 7.5–11.0%). HbA 1c was measured periodically over 1 year. Results Vildagliptin and metformin each rapidly decreased HbA 1c from an equal baseline of 8.7%. Most of the HbA 1c reduction was attained by week 12, and the efficacy was sustained throughout 1‐year treatment with both agents. At the study end, significant HbA 1c reductions from baseline were seen with both vildagliptin (–1.0 ± 0.1%, P < 0.001) and metformin (–1.4 ± 0.1%, P < 0.001); however, statistical non‐inferiority of 50 mg vildagliptin twice daily to 1000 mg metformin twice daily was not established. Body weight did not change during the 1‐year treatment with vildagliptin (0.3 ± 0.2 kg, P = 0.17) and decreased in metformin‐treated patients (–1.9 ± 0.3 kg, P < 0.001). The proportion of patients experiencing an adverse event was 70.1 vs. 75.4% in patients receiving vildagliptin and metformin, respectively. The proportion of patients experiencing a gastrointestinal adverse event was twofold higher in the metformin group, driven by a 3–4‐fold greater incidence of diarrhoea, nausea and abdominal pain. The incidence of hypoglycaemia was similarly low in both groups (< 1%). Conclusions A clinically meaningful decrease in HbA 1c that was sustained throughout a 1‐year treatment in drug‐naïve patients with Type 2 DM was seen with both metformin and vildagliptin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Self-citationHanefeld, M., Brunetti, P., Schernthaner, G. H., Matthews, D. R., Charbonnel, B. H., & on behalf of the QUARTET Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.1.141 · Cited by 230
Charbonnel, B., Schernthaner, G., Brunetti, P., Matthews, D. R., Urquhart, R., Tan, M. H., & Hanefeld, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1751-1 · Cited by 170
Cited by
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Metadata
- Authors
- Schweizer, A., Couturier, A., Foley, J. E., & Dejager, S.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2007-05-17
- Volume
- 24
- Issue
- 9
- Pages
- 955-961
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2020638064
- Cited by
- 240
- References
- 7
- FWCI
- 29.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1464-5491.2007.02191.x
- The paper
- Schweizer, A., Couturier, A., Foley, J. E., & Dejager, S. (2007). Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2007.02191.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.